Cardiomyocyte death in doxorubicin-induced cardiotoxicity

Yi Wei Zhang, Jianjian Shi, Yuan Jian Li, Lei Wei

Research output: Contribution to journalReview articlepeer-review

254 Scopus citations


Doxorubicin (DOX) is one of the most widely used and successful antitumor drugs, but its cumulative and dose-dependent cardiac toxicity has been a major concern of oncologists in cancer therapeutic practice for decades. With the increasing population of cancer survivors, there is a growing need to develop preventive strategies and effective therapies against DOX-induced cardiotoxicity, in particular late-onset cardiomyopathy. Although intensive investigations on DOX-induced cardiotoxicity have continued for decades, the underlying mechanisms responsible for DOX-induced cardiotoxicity have not been completely elucidated. A rapidly expanding body of evidence supports the notion that cardiomyocyte death by apoptosis and necrosis is a primary mechanism of DOX-induced cardiomyopathy and that other types of cell death, such as autophagy and senescence/aging, may participate in this process. This review focuses on the current understanding of the molecular mechanisms underlying DOX-induced cardiomyocyte death, including the major primary mechanism of excess production of reactive oxygen species (ROS) and other recently discovered ROS-independent mechanisms. The different sensitivities to DOX-induced cell death signals between adult and young cardiomyocytes will also be discussed.

Original languageEnglish (US)
Pages (from-to)435-445
Number of pages11
JournalArchivum Immunologiae et Therapiae Experimentalis
Issue number6
StatePublished - Dec 1 2009


  • Apoptosis
  • Autophagy
  • Cardiomyocyte
  • Doxorubicin
  • Necrosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Cardiomyocyte death in doxorubicin-induced cardiotoxicity'. Together they form a unique fingerprint.

Cite this